- Kane Biotech (OTCQB:KNBIF) on Thursday introduced that it signed a worldwide license settlement with Arizona-based Omni Bioceutical Improvements for its coactiv+ line of scalp care merchandise.
- The five-year non-exclusive settlement would see Omni commercialize Kane’s scalp detoxifier product below the Omni Bioceuticals model within the medical aesthetics market.
- Supply: Press Launch